Epidemiology of glial and non-glial brain tumours in Europe

Emanuele Crocetti, Annalisa Trama, Charles Stiller, Adele Caldarella, Riccardo Soffietti, Jana Jaal, Damien C. Weber, Umberto Ricardi, Jerzy Slowinski, Alba Brandes

Research output: Contribution to journalArticle

Abstract

To the central nervous system (CNS) belong a heterogeneous group of glial and non glial rare cancers. The aim of the present study was to estimate the burden (incidence, prevalence, survival and proportion of cured) for the principal CNS cancers in Europe (EU27) and in European regions using population-based data from cancer registries participating in the RARECARE project. We analysed 44,947 rare CNS cancers diagnosed from 1995 to 2002 (with follow up at 31st December 2003): 86.0% astrocytic (24% low grade, 63% high grade and 13% glioma NOS), 6.4% oligodendroglial (74% low grade), 3.6% ependymal (85% low grade), 4.1% Embryonal tumours and 0.1% choroid plexus carcinoma. Incidence rates vary widely across European regions especially for astrocytic tumours ranging from 3/100,000 in Eastern Europe to 5/100,000 in United Kingdom and Ireland. Overall, about 27,700 new rare CNS cancers were estimated every year in EU27, for an annual incidence rate of 4.8 per 100,000 for astrocytic, 0.4 for oligodendroglial, 0.2 for ependymal and embryonal tumours and less than 0.1 for choroid plexus carcinoma. More than 154,000 persons with rare CNS were estimated alive (prevalent cases) in the EU at the beginning of 2008. Five-year relative survival was 14.5% for astrocytic tumours (42.6% for low grade, 4.9% for high grade and 17.5% for glioma NOS), 54.5% for oligodendroglial (64.9% high grade and 29.6% low grade), 74.2% for ependymal (80.4% low grade and 36.6% high grade), 62.8% for choroid plexus carcinomas and 56.8% for embryonal tumours. Survival rates for astrocytic tumours were relatively higher in Northern and Central Europe than in Eastern Europe and in UK and Ireland. The different availability of diagnostic imaging techniques and/or radiation therapy equipment across Europe may contribute to explain the reported survival differences. The estimated proportion of cured patients was 7.9% for the 'glial' group to which belong astrocytic tumours. Overall results are strongly influenced by astrocytic tumours that are the most common type. This is the first study to delineate the rare CNS cancer burden in Europe by age, sex and European region.

Original languageEnglish
Pages (from-to)1532-1542
Number of pages11
JournalEuropean Journal of Cancer
Volume48
Issue number10
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Brain Neoplasms
Neuroglia
Epidemiology
Neoplasms
Central Nervous System
Eastern Europe
Ireland
Glioma
Survival
Incidence
Diagnostic Imaging
Registries
Radiotherapy
Survival Rate

Keywords

  • Central nervous system
  • Epidemiology
  • Estimates
  • Glial tumours
  • Incidence
  • Non-glial brain tumours
  • Prevalence
  • Rare cancer
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Crocetti, E., Trama, A., Stiller, C., Caldarella, A., Soffietti, R., Jaal, J., ... Brandes, A. (2012). Epidemiology of glial and non-glial brain tumours in Europe. European Journal of Cancer, 48(10), 1532-1542. https://doi.org/10.1016/j.ejca.2011.12.013

Epidemiology of glial and non-glial brain tumours in Europe. / Crocetti, Emanuele; Trama, Annalisa; Stiller, Charles; Caldarella, Adele; Soffietti, Riccardo; Jaal, Jana; Weber, Damien C.; Ricardi, Umberto; Slowinski, Jerzy; Brandes, Alba.

In: European Journal of Cancer, Vol. 48, No. 10, 07.2012, p. 1532-1542.

Research output: Contribution to journalArticle

Crocetti, E, Trama, A, Stiller, C, Caldarella, A, Soffietti, R, Jaal, J, Weber, DC, Ricardi, U, Slowinski, J & Brandes, A 2012, 'Epidemiology of glial and non-glial brain tumours in Europe', European Journal of Cancer, vol. 48, no. 10, pp. 1532-1542. https://doi.org/10.1016/j.ejca.2011.12.013
Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J et al. Epidemiology of glial and non-glial brain tumours in Europe. European Journal of Cancer. 2012 Jul;48(10):1532-1542. https://doi.org/10.1016/j.ejca.2011.12.013
Crocetti, Emanuele ; Trama, Annalisa ; Stiller, Charles ; Caldarella, Adele ; Soffietti, Riccardo ; Jaal, Jana ; Weber, Damien C. ; Ricardi, Umberto ; Slowinski, Jerzy ; Brandes, Alba. / Epidemiology of glial and non-glial brain tumours in Europe. In: European Journal of Cancer. 2012 ; Vol. 48, No. 10. pp. 1532-1542.
@article{5aa958b92eb449c0ad09aaaa04af7937,
title = "Epidemiology of glial and non-glial brain tumours in Europe",
abstract = "To the central nervous system (CNS) belong a heterogeneous group of glial and non glial rare cancers. The aim of the present study was to estimate the burden (incidence, prevalence, survival and proportion of cured) for the principal CNS cancers in Europe (EU27) and in European regions using population-based data from cancer registries participating in the RARECARE project. We analysed 44,947 rare CNS cancers diagnosed from 1995 to 2002 (with follow up at 31st December 2003): 86.0{\%} astrocytic (24{\%} low grade, 63{\%} high grade and 13{\%} glioma NOS), 6.4{\%} oligodendroglial (74{\%} low grade), 3.6{\%} ependymal (85{\%} low grade), 4.1{\%} Embryonal tumours and 0.1{\%} choroid plexus carcinoma. Incidence rates vary widely across European regions especially for astrocytic tumours ranging from 3/100,000 in Eastern Europe to 5/100,000 in United Kingdom and Ireland. Overall, about 27,700 new rare CNS cancers were estimated every year in EU27, for an annual incidence rate of 4.8 per 100,000 for astrocytic, 0.4 for oligodendroglial, 0.2 for ependymal and embryonal tumours and less than 0.1 for choroid plexus carcinoma. More than 154,000 persons with rare CNS were estimated alive (prevalent cases) in the EU at the beginning of 2008. Five-year relative survival was 14.5{\%} for astrocytic tumours (42.6{\%} for low grade, 4.9{\%} for high grade and 17.5{\%} for glioma NOS), 54.5{\%} for oligodendroglial (64.9{\%} high grade and 29.6{\%} low grade), 74.2{\%} for ependymal (80.4{\%} low grade and 36.6{\%} high grade), 62.8{\%} for choroid plexus carcinomas and 56.8{\%} for embryonal tumours. Survival rates for astrocytic tumours were relatively higher in Northern and Central Europe than in Eastern Europe and in UK and Ireland. The different availability of diagnostic imaging techniques and/or radiation therapy equipment across Europe may contribute to explain the reported survival differences. The estimated proportion of cured patients was 7.9{\%} for the 'glial' group to which belong astrocytic tumours. Overall results are strongly influenced by astrocytic tumours that are the most common type. This is the first study to delineate the rare CNS cancer burden in Europe by age, sex and European region.",
keywords = "Central nervous system, Epidemiology, Estimates, Glial tumours, Incidence, Non-glial brain tumours, Prevalence, Rare cancer, Survival",
author = "Emanuele Crocetti and Annalisa Trama and Charles Stiller and Adele Caldarella and Riccardo Soffietti and Jana Jaal and Weber, {Damien C.} and Umberto Ricardi and Jerzy Slowinski and Alba Brandes",
year = "2012",
month = "7",
doi = "10.1016/j.ejca.2011.12.013",
language = "English",
volume = "48",
pages = "1532--1542",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "10",

}

TY - JOUR

T1 - Epidemiology of glial and non-glial brain tumours in Europe

AU - Crocetti, Emanuele

AU - Trama, Annalisa

AU - Stiller, Charles

AU - Caldarella, Adele

AU - Soffietti, Riccardo

AU - Jaal, Jana

AU - Weber, Damien C.

AU - Ricardi, Umberto

AU - Slowinski, Jerzy

AU - Brandes, Alba

PY - 2012/7

Y1 - 2012/7

N2 - To the central nervous system (CNS) belong a heterogeneous group of glial and non glial rare cancers. The aim of the present study was to estimate the burden (incidence, prevalence, survival and proportion of cured) for the principal CNS cancers in Europe (EU27) and in European regions using population-based data from cancer registries participating in the RARECARE project. We analysed 44,947 rare CNS cancers diagnosed from 1995 to 2002 (with follow up at 31st December 2003): 86.0% astrocytic (24% low grade, 63% high grade and 13% glioma NOS), 6.4% oligodendroglial (74% low grade), 3.6% ependymal (85% low grade), 4.1% Embryonal tumours and 0.1% choroid plexus carcinoma. Incidence rates vary widely across European regions especially for astrocytic tumours ranging from 3/100,000 in Eastern Europe to 5/100,000 in United Kingdom and Ireland. Overall, about 27,700 new rare CNS cancers were estimated every year in EU27, for an annual incidence rate of 4.8 per 100,000 for astrocytic, 0.4 for oligodendroglial, 0.2 for ependymal and embryonal tumours and less than 0.1 for choroid plexus carcinoma. More than 154,000 persons with rare CNS were estimated alive (prevalent cases) in the EU at the beginning of 2008. Five-year relative survival was 14.5% for astrocytic tumours (42.6% for low grade, 4.9% for high grade and 17.5% for glioma NOS), 54.5% for oligodendroglial (64.9% high grade and 29.6% low grade), 74.2% for ependymal (80.4% low grade and 36.6% high grade), 62.8% for choroid plexus carcinomas and 56.8% for embryonal tumours. Survival rates for astrocytic tumours were relatively higher in Northern and Central Europe than in Eastern Europe and in UK and Ireland. The different availability of diagnostic imaging techniques and/or radiation therapy equipment across Europe may contribute to explain the reported survival differences. The estimated proportion of cured patients was 7.9% for the 'glial' group to which belong astrocytic tumours. Overall results are strongly influenced by astrocytic tumours that are the most common type. This is the first study to delineate the rare CNS cancer burden in Europe by age, sex and European region.

AB - To the central nervous system (CNS) belong a heterogeneous group of glial and non glial rare cancers. The aim of the present study was to estimate the burden (incidence, prevalence, survival and proportion of cured) for the principal CNS cancers in Europe (EU27) and in European regions using population-based data from cancer registries participating in the RARECARE project. We analysed 44,947 rare CNS cancers diagnosed from 1995 to 2002 (with follow up at 31st December 2003): 86.0% astrocytic (24% low grade, 63% high grade and 13% glioma NOS), 6.4% oligodendroglial (74% low grade), 3.6% ependymal (85% low grade), 4.1% Embryonal tumours and 0.1% choroid plexus carcinoma. Incidence rates vary widely across European regions especially for astrocytic tumours ranging from 3/100,000 in Eastern Europe to 5/100,000 in United Kingdom and Ireland. Overall, about 27,700 new rare CNS cancers were estimated every year in EU27, for an annual incidence rate of 4.8 per 100,000 for astrocytic, 0.4 for oligodendroglial, 0.2 for ependymal and embryonal tumours and less than 0.1 for choroid plexus carcinoma. More than 154,000 persons with rare CNS were estimated alive (prevalent cases) in the EU at the beginning of 2008. Five-year relative survival was 14.5% for astrocytic tumours (42.6% for low grade, 4.9% for high grade and 17.5% for glioma NOS), 54.5% for oligodendroglial (64.9% high grade and 29.6% low grade), 74.2% for ependymal (80.4% low grade and 36.6% high grade), 62.8% for choroid plexus carcinomas and 56.8% for embryonal tumours. Survival rates for astrocytic tumours were relatively higher in Northern and Central Europe than in Eastern Europe and in UK and Ireland. The different availability of diagnostic imaging techniques and/or radiation therapy equipment across Europe may contribute to explain the reported survival differences. The estimated proportion of cured patients was 7.9% for the 'glial' group to which belong astrocytic tumours. Overall results are strongly influenced by astrocytic tumours that are the most common type. This is the first study to delineate the rare CNS cancer burden in Europe by age, sex and European region.

KW - Central nervous system

KW - Epidemiology

KW - Estimates

KW - Glial tumours

KW - Incidence

KW - Non-glial brain tumours

KW - Prevalence

KW - Rare cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84862016066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862016066&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2011.12.013

DO - 10.1016/j.ejca.2011.12.013

M3 - Article

C2 - 22227039

AN - SCOPUS:84862016066

VL - 48

SP - 1532

EP - 1542

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 10

ER -